SEC Info - Ziopharm Oncology Inc - ‘8-K’ for 1/20/11

SEC Info℠

Home

Help

Please Sign In

Ziopharm Oncology Inc – ‘8-K’ for 1/20/11

On: Wednesday, 1/26/11, at 9:13am ET · For: 1/20/11 · Accession #: 1144204-11-4065 · File #: 1-33038

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/26/11  Ziopharm Oncology Inc             8-K:8,9     1/20/11    2:51K                                    Vintage/FA

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K

8-K — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 20, 2011

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-33038		84-1475642
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1180 Avenue of the Americas 19th Floor New York, NY		10036
(Address of Principal Executive Offices)		(Zip Code)

(646) 214-0700

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

On January 20, 2011, ZIOPHARM Oncology, Inc. (the “Company”) issued a press release announcing that The Committee for Orphan Medicinal Products within the European Medicines Agency adopted a positive opinion for the designation of darinaparsin' (Zinapar™ or ZIO-101) as an orphan medicinal product for the treatment of peripheral T-cell lymphoma. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits.

(d)	Exhibits

	Exhibit No.	Description
	99.1	Press Release dated January 20, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZIOPHARM Oncology, Inc.


	By:	/s/ Richard Bagley
Date: January 26, 2011		Name: Richard Bagley
		Title: President, Chief Operating Officer and Chief Financial Officer

INDEX OF EXHIBITS

Exhibit No.		Description

99.1		Press Release dated January 20, 2011

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	1/26/11
For Period End:	1/20/11	SC 13D
		List all Filings

↑Top

Filing Submission 0001144204-11-004065 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)